MSD Animal Health has launched the first tetravalent Leptospirosis vaccine in Europe. Nobivac L4 provides immunity against serovars from the four key leptospirosis serogroups present in Europe.
MSD Animal Health has launched Nobivac L4, the first tetravalent leptospirosis vaccine in Europe.
Historically, bivalent leptospirosis vaccines have been used to immunise dogs, but changes in the epidemiology have left dogs open to contracting the disease through contact with other leptospira serovars not covered by current vaccines.
Produced by MSD Animal Health, Nobivac L4 can be used in place of the current bivalent vaccines and provides immunity against serovars from the four key leptospirosis serogroups present in Europe.
Administered from six weeks with a follow up vaccination four weeks later, the product offers 12 months protection and has claims against renal shedding of the infectious leptospires, reducing the risk of dog to dog and human infection.
Additionally, an innovative washing and filtering process (Vaccipure™) has been used in the production of the vaccine to actively remove Bovine Serum Albumin (BSA) – a common component used in many vaccines to produce leptospira antigens, but which has been linked with hypersensitivity reactions that can occur following vaccination.
- Nobivac L4 is now available from wholesalers.